quality control comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Stability testing examines how purity changes under controlled conditions. Samples are stored at defined temperatures, such as -20 °C or -80 °C, and analyzed at intervals. Lyophilized powders are generally more stable than solutions because water promotes hydrolysis and aggregation. Repeated freeze-thaw cycles can also degrade peptides, especially those with oxidation-prone residues. Accelerated studies at elevated temperature provide useful comparisons, but they do not always predict long-term behavior at lower temperatures.
Handling practices influence measured purity. Peptides may adsorb to plastic or glass surfaces, particularly when hydrophobic or positively charged. Weighing hygroscopic powders can introduce water and alter concentration. Dissolving in appropriate solvents and using low-binding tubes can reduce losses. Each laboratory should validate its own procedures because recovery and stability vary with peptide sequence, formulation, and container material. Open questions remain about how best to standardize stability reporting across different peptide classes.
Purity results are only meaningful when linked to a defined sample and method. A certificate of analysis typically lists the analytical technique, column type, gradient, detection wavelength, and integration parameters. It may also report mass confirmation, water content, and counterion composition. For research peptides, laboratories often request the raw chromatogram rather than only a summary percentage. This allows independent review of baseline, peak shape, and any unresolved shoulders that might be missed by a single number.
Impurity profiling identifies and quantifies substances that coexist with the target peptide. These include deletion sequences, truncated peptides, oxidized variants, and residual protecting groups from synthesis. Reversed-phase chromatography can separate many of these impurities, but co-elution remains a challenge for closely related species. Mass spectrometry helps assign identities to impurity peaks, and impurity limits are often set as area percentages relative to the main peak. Regulatory guidelines for research-grade peptides are less strict than those for therapeutic products, so specifications vary by supplier.
Quality control for peptides involves setting specifications for identity, purity, and counterion content. Batches are tested against these specifications before release. Purity specifications often require a minimum area percentage by high-performance liquid chromatography, such as 95% or 98%, depending on the intended application. Additional tests may include water content, acetate or trifluoroacetate content, and residual solvents. These parameters affect the net peptide content and the accuracy of subsequent laboratory experiments.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or -80 °C | Lyophilized powder, desiccated and protected from light |
| Solution storage | -20 °C or -80 °C in aliquots | Avoid repeated freeze-thaw cycles |
| Common counterion | Trifluoroacetate (TFA) | Often present from HPLC purification; affects mass and pH |
| Water content method | Karl Fischer titration | Measures residual moisture in lyophilized powder |
| Stability indicator | Appearance and re-analysis by HPLC | Visible changes are limited; chromatographic purity is more informative |
Other chromatographic modes provide complementary information that reverse-phase separation may not capture. Ion-exchange chromatography separates peptides by net charge and can resolve deamidated, oxidized, or truncated variants that co-elute under hydrophobic conditions. Size-exclusion chromatography detects aggregates and higher-order oligomers, which are often invisible in reverse-phase assays. Chiral chromatography can quantify D-amino acid epimers when stereochemical purity matters. Because each mode uses a different separation principle, a single purity number from one method cannot describe all possible impurities.
Interpreting chromatographic purity requires attention to detection limits and response factors. Peptides without aromatic residues may absorb weakly at 280 nm, so 214 nm is often preferred, but mobile-phase additives and solvents also absorb at low wavelengths. Co-eluting impurities with different molar absorptivities can produce area percentages that differ from mass percentages. Integration parameters, peak tailing, and baseline choice further affect reported values. For these reasons, method details belong alongside any purity figure, and orthogonal methods are needed to confirm identity and impurity profiles.
Peptide purity testing measures how much of a sample consists of the intended peptide sequence compared with related substances, water, counterions, and residual solvents. No single analytical method captures all of these components at once. Reversed-phase high-performance liquid chromatography with ultraviolet detection is widely used because it separates peptides by hydrophobicity. The reported purity value therefore depends on the chosen method, column, mobile phase, and detection wavelength. Established practice treats purity as method-dependent rather than an absolute property of the material.
Chromatographic separation resolves truncated, oxidized, deamidated, and epimerized peptide variants when their retention times differ from the target. Mass spectrometry confirms molecular mass and can reveal modifications that UV detection misses. Liquid chromatography coupled to mass spectrometry combines separation with identity information, which helps distinguish a pure target from a co-eluting impurity. UV-based area percent can overestimate purity if an impurity lacks a chromophore or if the target and impurity have similar response factors. Researchers often report both chromatographic purity and mass confirmation to give a fuller picture.
Peptide purity testing uses separation methods to estimate the proportion of a sample that corresponds to the target sequence. Reverse-phase high-performance liquid chromatography is the most common technique, separating peptides by hydrophobicity on a nonpolar column. Ultraviolet detection at 214 nm records peptide bonds and aromatic residues. The resulting chromatogram is reported as area percent, which reflects relative absorbance rather than absolute mass. This distinction matters because water, counterions, and residual solvents do not appear in the peptide peak.
Mass spectrometry provides an identity check that complements chromatographic purity. Electrospray ionization or matrix-assisted laser desorption/ionization measures the mass-to-charge ratio of intact peptides. A match to the expected molecular mass supports correct sequence length and terminal groups. Mass accuracy alone does not prove that every peak in a liquid chromatogram is the target peptide. It also does not directly quantify how much water or counterion remains in a lyophilized powder.
Orthogonal methods reduce the chance that a single technique misses an impurity. Capillary electrophoresis separates by charge-to-size ratio and can resolve variants that co-elute under one set of HPLC conditions. Amino acid analysis reports composition after hydrolysis and confirms the presence of expected residues. Karl Fischer titration measures water content, while ion chromatography can quantify counterions. No single number captures all aspects of sample quality, so reports often combine several measurements.
Reported purity values can differ between laboratories even for the same sample. Variations arise from column chemistry, mobile-phase composition, gradient slope, detection wavelength, injection load, and integration rules. Area percent also assumes that all species have similar response factors, which is not always true. Method validation examines specificity, linearity, accuracy, precision, limit of detection, and limit of quantitation. When comparing certificates, the method description and representative chromatogram are as important as the headline percentage.
Purity and potency are related but distinct concepts in peptide testing. Purity describes the proportion of the main peptide relative to other detected substances, while potency refers to the biological or functional activity of a defined amount. A highly pure peptide can still have low potency if it is misfolded, aggregated, or chemically modified at a critical residue. Conversely, a less pure preparation may retain high activity if the impurities are inactive. Clear reporting separates these attributes and states the assay used for each.
Beta-lactamase Dihydrofolate reductase (DHFR) Focal adhesion kinase (FAK) Gal4, a yeast transcription factor (as in the classical yeast two-hybrid system) GFP (split-GFP), e.g. EGFP (enhanced green fluorescent protein) Horseradish peroxidase Infrared fluorescent protein IFP1.4, an engineered chromophore-binding domain (CBD) of a bacteriophytochrome from Deinococcus radiodurans LacZ (beta-galactosidase) Luciferase, including ReBiL (recombinase enhanced bimolecular luciferase) and Gaussia princeps luciferase. Commercial products using luciferase include NanoLuc and NanoBIT. A modification has also been developed for lipid droplet-associated interactions. FAST (splitFAST) TEV (Tobacco etch virus protease) Ubiquitin The methods mentioned above have been applied to whole genomes, e.g. yeast or syphilis bacteria.
Camurus aims to collaborate with biotechnology and pharmaceutical companies worldwide to enable and improve the delivery of a wide range of drug compounds. These compounds including peptides, proteins, and insoluble small molecules make use of delivery solutions ranging from long-acting depots to lipid nanocarriers designed for improved intravenous, transdermal, and oral delivery. Camurus' in-house product portfolio targets healthcare needs in areas of growth-hormone disorders, cancer, oncology supportive care, metabolic disease, and drug addiction. In 2007, British investors evaluated six nominated private companies and chose to Camurus as the best privately owned biotechnology company in the Medicon Valley. The company was awarded the Strictly Financing Award 2007. In 2013, Camurus was awarded CPhI Pharma Award for Best Innovation in Formulation.
=== 2006–2013: Rise to prominence and subsequent hiatus === Larter auditioned for the science fiction drama television series Heroes on NBC while living in Los Angeles. She played the characters of Niki Sanders, who suffered from dissociative identity disorder, and Tracy Strauss on the show created by Tim Kring. Larter's initial character Niki Sanders, was a wife, mother, and a former internet stripper from Las Vegas exhibiting superhuman strength and alternate personalities who go by the names of Jessica and Niki. "Ali read for the part and just owned it from the second she walked in," Kring said to the Chicago Tribune, "It was a very impressive audition." In the third and fourth seasons, Larter played the new character of Tracy Strauss, who possessed the ability to freeze objects and later, transform her body into water. Larter took on the title role in Marigold (2007), alongside Salman Khan, an Indian actor. The film was released in August 2007 and revolved around Marigold Lexington, an American actress (Larter) who goes to India and gets caught up in the exotic world of Bollywood. Filming took place in North India and London, commencing in June 2004. In an interview with the BBC, Larter remarked this role was "an opportunity to overcome my fear of singing and dancing because I have no professional training... I really focused on the character and loved this journey she went on and the experiences she had." She was paid a seven-figure salary for her part in the film.
=== Platyspondylic lethal skeletal dysplasia, Torrance type === Fewer than 10 COL2A1 mutations have been identified in people with platyspondylic lethal skeletal dysplasia, Torrance type. Most result in a single amino acid change in the pro-alpha1(II) chain, producing an abnormal chain that cannot be incorporated into collagen fibers. This leads to reduced collagen production and skeletal abnormalities such as short limbs, small chest, flattened vertebrae, and short fingers and toes.
== Overview == FACIT collagens have interruptions in their triple helical structure. They are involved in assembling fibrillar collagens and other ECM components. Interruptions in the triple helical structure of FACIT collagens occur due to the presence of non-triple helical domains within the collagen molecule. These collagens are typically found alongside fibrillar collagens in various tissues and organs. Fibril-associated collagens with interrupted triple helices (FACIT collagens) are a subset of collagens that contribute to the organization and stabilization of the extracellular matrix (ECM). These collagens are typically found alongside fibrillar collagens in various tissues and organs. These domains vary in length and composition and provide flexibility and additional binding sites for other components of the extracellular matrix. There are eight known types of FACIT collagens: collagens IX, XII, XIV, XVI, XIX, XXI, and XXII. The general FACIT collagen structure contains short triple helical COL domains (COL1, COL2, COL3) interrupted by NC domains with an N-terminal NC domain facing toward the interfibrillar space. FACIT collagen is found in various tissue areas to modulate the surface properties of collagen fibrils and generate tissue-specific three-dimensional patterns in the extracellular matrix. For example, collagen XIV connects the fibrillar networks of the cartilage and skin, and XII is found in connective tissues, particularly at the tendons, ligaments, and periodontium.
Sources: en.wikipedia.org
=== Excessive sugar intake === Too much sugar intake can negatively impact the body, including damage to collagen. Excess sugar consumption results in glycation that produces AGEs. This occurs naturally, and when too much sugar is consumed, the AGE molecules stick to the collagen molecules turning them stiff, thus damaging them. The process of glycation does not only damage the collagen existing in the body but also makes some alterations to its stability. When an individual consumes excessive amounts of sugar, the glycation process converts collagen into an unstable type 1, which becomes more vulnerable and can be easily broken down, potentially leading to premature aging.
=== Vascular type Ehlers-Danlos syndrome === Some patients with Vascular type Ehlers-Danlos, which is caused by mutations in COL3alpha1, are known to also have mutations in the COL1alpha1 gene. However the exact associations remain unknown.
A major factor is mechanical deformation of the extracellular matrix, which can affect the actin cytoskeleton and therefore affect cell shape, motility, and function. Mechanical forces can be transmitted by focal adhesion sites, integrins, and cell-cell junctions. Changes in the actin cytoskeleton can activate integrins, which mediate "outside-in" and "inside-out" signaling between the cell and the matrix. G-proteins, which induce intracellular signaling cascades, may also be important, and ion channels are activated by stretching to allow ions such as calcium, sodium, or potassium to enter the cell.
In some organisms, notably birds, and ornithischian dinosaurs, portions of the tendon can become ossified. In this process, osteocytes infiltrate the tendon and lay down bone as they would in sesamoid bone such as the patella. In birds, tendon ossification primarily occurs in the hindlimb, while in ornithischian dinosaurs, ossified axial muscle tendons form a latticework along the neural and haemal spines on the tail, presumably for support.
Sources: en.wikipedia.org
Several studies have demonstrated that tendons respond to changes in mechanical loading with growth and remodeling processes, much like bones. In particular, a study showed that disuse of the Achilles tendon in rats resulted in a decrease in the average thickness of the collagen fiber bundles comprising the tendon. In humans, an experiment in which people were subjected to a simulated micro-gravity environment found that tendon stiffness decreased significantly, even when subjects were required to perform restiveness exercises. These effects have implications in areas ranging from treatment of bedridden patients to the design of more effective exercises for astronauts.
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup A10 is part of the anatomical group A Alimentary tract and metabolism. Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QA10. National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version. A10AB01 Insulin (human) A10AB02 Insulin (beef) A10AB03 Insulin (pork) A10AB04 Insulin lispro A10AB05 Insulin aspart A10AB06 Insulin glulisine A10AB30 Combinations === A10AC Insulins and analogues for injection, intermediate-acting === A10AC01 Insulin (human) A10AC02 Insulin (beef) A10AC03 Insulin (pork) A10AC04 Insulin lispro A10AC30 Combinations
== Causes == Mutations in the COL11A1, COL11A2, and COL2A1 genes cause collagenopathy, types II and XI. These genes carry instructions for the protein strands that make up type II and type XI collagen. All collagen molecules are made of three protein strands (called alpha chains). The alpha chains may be identical or different, depending on the type of collagen. Type II collagen is made by combining three copies of the alpha chain made by the COL2A1 gene. Type XI collagen, on the other hand, is composed of three different alpha chains: the products of the COL2A1, COL11A1, and COL11A2 genes. Mutations in these genes interfere with the proper assembly of type II and XI collagens or reduce the amount of these collagens. Defective or reduced numbers of collagen molecules affect the development of bones and other connective tissues, causing the signs and symptoms of the type II and XI collagenopathies.
Sources: en.wikipedia.org
It typically includes the peptide sequence, molecular mass, purity method and result, storage recommendations, and date of analysis. Raw chromatograms and mass spectra may be provided on request. The absence of method details makes a purity value difficult to interpret.
Most lyophilized peptides are stored desiccated at -20 °C or lower, protected from light. Solutions are often aliquoted and frozen to avoid repeated freeze-thaw cycles. The optimal conditions depend on sequence, solubility, and intended duration of storage.
Hydrolysis, oxidation, deamidation, and aggregation can alter the amount of intact peptide. Stability depends on sequence, water content, temperature, pH, and container. Periodic re-analysis is the reliable way to detect changes, because visual inspection cannot reveal most degradation.
Lyophilized peptides are typically stored at -20 °C or lower, protected from moisture and light. Solutions are often stored at -80 °C and divided into single-use aliquots. Repeated freeze-thaw cycles should be avoided.